Evidence map›Paper›PMID 30061884›Full record

ArticleFrontiers in immunology2018

P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis.

Laura Rennert, Stefan Zschiedrich, Lukas Sandner, Björn Hartleben, Sanja Cicko, Cemil Korcan Ayata, Charlotte Meyer, Andreas Zech, Robert Zeiser, Tobias B Huber and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Inhibition of (interstitial) P2YPflugers Archiv : European journal of physiology · 2026
    Article
  2. Inhibition of (interstitial) P2YResearch square · 2026
    Article
  3. Inhibition of (interstitial) P2YbioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Therapeutic potential for P2YPurinergic signalling · 2023
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Laura RennertDepartment of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Stefan ZschiedrichDepartment of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Lukas SandnerDepartment of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Björn HartlebenDepartment of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Sanja CickoDepartment of Pneumology, University Medical Center Freiburg, Freiburg, Germany.
Cemil Korcan AyataDepartment of Pneumology, University Medical Center Freiburg, Freiburg, Germany.
Charlotte MeyerDepartment of Pneumology, University Medical Center Freiburg, Freiburg, Germany.
Andreas ZechDepartment of Pneumology, University Medical Center Freiburg, Freiburg, Germany.
Robert ZeiserDepartment of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany.
Tobias B HuberDepartment of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Marco IdzkoDepartment of Pneumology, University Medical Center Freiburg, Freiburg, Germany.
Florian GrahammerDepartment of Medicine IV, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
University Medical Center Freiburg · DEUniversity of Freiburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

European Research Council 616891
6 · The paper itself

Abstract

Endogenously released adenosine-5'-triphosphate (ATP) is a key regulator of physiological function and inflammatory responses in the kidney. Genetic or pharmacological inhibition of purinergic receptors has been linked to attenuation of inflammatory disorders and hence constitutes promising new avenues for halting and reverting inflammatory renal diseases. However, the involvement of purinergic receptors in glomerulonephritis (GN) has only been incompletely mapped. Here, we demonstrate that induction of GN in an experimental antibody-mediated GN model results in a significant increase of urinary ATP-levels and an upregulation of P2Y2R expression in resident kidney cells as well as infiltrating leukocytes pointing toward a possible role of the ATP/P2Y2R-axis in glomerular disease initiation. In agreement, decreasing extracellular ATP-levels or inhibition of P2R during induction of antibody-mediated GN leads to a reduction in all cardinal features of GN such as proteinuria, glomerulosclerosis, and renal failure. The specific involvement of P2Y2R could be further substantiated by demonstrating the protective effect of the lack of P2Y2R in antibody-mediated GN. To systematically differentiate between the function of P2Y2R on resident renal cells versus infiltrating leukocytes, we performed bone marrow-chimera experiments revealing that P2Y2R on hematopoietic cells is the main driver of the ATP/P2Y2R-mediated disease progression in antibody-mediated GN. Thus, these data unravel an important pro-inflammatory role for P2Y2R in the pathogenesis of GN.

Indexed as

adenosine-5’-triphosphateanimal modelglomerulonephritisleukocytesP2Y2purinergic receptors

Identifiers

PMID30061884
PMCPMC6054981
OpenAlexW2883775757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.